Gilead Sciences: O'Day proposes $7.60M share sale

The proposed shares include 15,881 acquired through stock-option exercise and 30,000 from performance stock units.

Rhea-AI Filing Summary

Gilead Sciences, Inc. officer and director Daniel O'Day reported a proposed sale of 45,881 common shares, with an approximate sale date of October 30, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. The stated aggregate market value is $7,598,352.41. His reported 10b5-1 sales in the preceding three months included 15,000 shares on October 1, 2026, for $2,218,507.50; 15,000 shares on September 1, 2026, for $2,229,592.50; and 15,000 shares on August 3, 2026, for $1,954,693.80.

Key Figures

Common shares proposed for sale: 45,881 shares Aggregate market value: $7,598,352.41 Shares acquired through stock-option exercise: 15,881 shares +5 more

8 metrics

Common shares proposed for sale 45,881 shares Approximate sale date: October 30, 2026

Aggregate market value $7,598,352.41 Proposed sale of common shares

Shares acquired through stock-option exercise 15,881 shares October 30, 2026

Shares from performance stock units 30,000 shares Dated February 4, 2025

Gross proceeds from October 1, 2026 sale $2,218,507.50 10b5-1 sale of 15,000 shares

Gross proceeds from September 1, 2026 sale $2,229,592.50 10b5-1 sale of 15,000 shares

Gross proceeds from August 3, 2026 sale $1,954,693.80 10b5-1 sale of 15,000 shares

Issuer shares outstanding 1,240,338,614 shares Reported in the Form 144 securities-to-be-sold information

Key Terms

Rule 144, 10b5-1 Sales, Performance Stock Units, Exercise of Stock Options

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 Sales regulatory

"10b5-1 Sales for Daniel O'Day"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Performance Stock Units financial

"Performance Stock Units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Exercise of Stock Options financial

"Exercise of Stock Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares is Daniel O'Day proposing to sell?

Daniel O'Day reported a proposed sale of 45,881 common shares, with an approximate sale date of October 30, 2026. The transaction lists Morgan Stanley Smith Barney LLC as broker, NASDAQ as the exchange, and an aggregate market value of $7,598,352.41.

How were the GILD shares in Daniel O'Day's proposed sale acquired?

The shares listed include 15,881 common shares acquired through exercise of stock options on October 30, 2026, and 30,000 common shares from performance stock units dated February 4, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 04:29 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:28 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001638643
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	GILEAD SCIENCES, INC
SEC File Number	000-19731
Address of Issuer	333 Lakeside Drive Foster City CALIFORNIA 94404
Phone	6505743000
Name of Person for Whose Account the Securities are To Be Sold	DANIEL O'DAY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45881	7598352.41	1240338614	10/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/30/2026	Exercise of Stock Options	Issuer			15881	10/30/2026	Cash
Common	02/04/2025	Performance Stock Units	Issuer			30000	02/04/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANIEL O'DAY 333 Lakeside Drive Foster City CA 94404	Common	10/01/2026	15000	2218507.50
10b5-1 Sales for DANIEL O'DAY 333 Lakeside Drive Foster City CA 94404	Common	09/01/2026	15000	2229592.50
10b5-1 Sales for DANIEL O'DAY 333 Lakeside Drive Foster City CA 94404	Common	08/03/2026	15000	1954693.80

144: Remarks and Signature

Remarks
Date of Notice	10/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel O'Day
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)